⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ImmunityBio, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ImmunityBio, Inc.
↗Culver City, California, USA
ImmunityBio is a vertically-integrated biotechnology company focused on developing next-generation immunotherapies and vaccines that activate the natural immune system to defeat cancers and infectious diseases. The company utilizes a range of platforms, including interleukin-15 (IL-15) fusion proteins, natural killer (NK) cell therapies, and adenovirus-vectored vaccines.
Following the FDA approval of its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), in 2024 for non-muscle invasive bladder cancer, the company has transitioned into a commercial-stage organization. It is actively scaling manufacturing and expanding its clinical pipeline to address various solid tumors and infectious diseases.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$500M
Founded:2014
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:IBRX
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (ANKTIVA)
Modalities:Immunotherapy, Cell therapy, NK cell therapy, Adenovirus-vectored vaccines
Active Trials:11
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Accord Healthcare (European commercialization), Serum Institute of India (BCG supply)
COMPETITION
Position:Emerging
Competitors:GT Biopharma, MiNK Therapeutics, Novocure, Oncolytics Biotech
LEADERSHIP
Key Executives:
Patrick Soon-Shiong - Founder, Executive Chairman, and Global Chief Scientific and Medical Officer
Richard Adcock - CEO
Scientific Founders:Patrick Soon-Shiong
LINKS
Website:immunitybio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ImmunityBio, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.